Modality
siRNA
MOA
DLL3 ADC
Target
IL-23
Pathway
PI3K/AKT
MCL
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
Sep 2018
→ Sep 2029
Phase 1Current
NCT03185030
2,604 pts·MCL
2018-09→2029-09·Active
2,604 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-103.4y awayPh2 Data· MCL
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Active
Catalysts
Ph2 Data
2029-09-10 · 3.4y away
MCL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03185030 | Phase 1/2 | MCL | Active | 2604 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Gelisertib | Samsung Biologics | Approved | IL-23 | |
| Talafotisoran | Blueprint Medicines | Phase 2/3 | IL-23 |